Clinical Trials
22 trialsNCT07527221 2026-06-01
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Recruiting
NCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT07549516 2026-05-15
ASC2ADHERE
Novartis
Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04925479 2026-04-30
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Novartis
Phase 1/2 Recruiting
NCT06514534 2026-04-21
ASC4TARGET
Novartis
Phase 2 Recruiting
NCT05943522 2026-04-20
Asciminib RMP Study
Novartis
Recruiting
NCT06297161 2026-04-14
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Pfizer
Recruiting
NCT05304377 2026-04-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT06994676 2026-03-16
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Phase 1 Recruiting
NCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT06163430 2026-01-12
CARDINAL
Terns, Inc.
Phase 1/2 Recruiting
NCT04260022 2025-11-05
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT07145411 2025-08-28
HOPE
Ossium Health, Inc.
Recruiting
NCT06787144 2025-07-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT05282108 2025-03-26
CARCML
Hikma Pharmaceuticals LLC
Recruiting
NCT06088888 2025-02-21
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd.
Phase 1 Recruiting
NCT06453902 2025-02-21
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
Phase 2 Recruiting
NCT03459534 2024-10-28
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Phase 3 Recruiting
NCT04835584 2022-03-21
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Phase 1/2 Recruiting